Key result
Trimetazidine lowers oxidative stress and reduces plasma BNP levels in chronic cor pulmonale.
Why the study?
An oxidant/antioxidant imbalance favoring oxidants occurs in chronic cor pulmonale, and oxidative stress may be critical in its pathogenesis, prompting investigation of trimetazidine's effects.
Does trimetazidine improve antioxidant enzyme activities and reduce plasma BNP levels in patients with chronic cor pulmonale?
RCT (n=60)
randomly allocated
Does trimetazidine improve antioxidant enzyme activities and reduce plasma BNP levels in patients with chronic cor pulmonale?
Trimetazidine added to routine treatment improves antioxidant levels, decreases oxidative stress, and lowers plasma BNP levels in patients with chronic cor pulmonale.
Answers are grounded in this paper and cite their sources.
Supports adjunctive trimetazidine in chronic cor pulmonale; extends antioxidant and BNP benefits to this population.
An oxidant/antioxidant imbalance in favour of oxidants appears to occur in chronic cor pulmonale (CCP). Oxidative stress could also be a critical event in the pathogenesis of this condition. Trimetazidine (TMZ) has antioxidant properties and may affect the utilization of oxygen radicals. We investigated the effect of TMZ (20 mg three times daily, orally) on activities of erythrocyte malondialdehyde (MDA) and catalase (eCAT), erythrocyte and plasma glutathione peroxidase (GSH-Px) and plasma superoxide dismutase (pSOD) in CCP patients. We also assessed changes in plasma levels of brain natriuretic peptide (BNP) with TMZ therapy. Sixty CCP patients with significantly higher MDA and markedly lower pSOD, eCAT and GSH-Px (erythrocyte) activities than 24 healthy controls were randomly allocated to receive routine treatment or routine treatment plus TMZ. After 3 months' therapy, greater pSOD, eCAT and GSH-Px (erythrocyte and plasma) activities and lower MDA activity were found with TMZ treatment compared with routine treatment. Plasma BNP levels were significantly lower in TMZ-treated patients and higher in the routine treatment group than in the control group. TMZ improved antioxidant levels, decreased oxidative stress and decreased plasma BNP levels in CCP patients.
No takes yet. Share an insight, caveat, or question.
Bayram et al. (2005) conducted an RCT in Chronic Cor Pulmonale (n=60). Trimetazidine vs. Routine treatment was evaluated on Erythrocyte malondialdehyde (MDA), catalase (eCAT), glutathione peroxidase (GSH-Px), plasma superoxide dismutase (pSOD) activities, and plasma BNP levels. Trimetazidine added to routine treatment for 3 months improved antioxidant levels, decreased oxidative stress, and decreased plasma BNP levels in patients with chronic cor pulmonale.
Synapse has enriched 10 related papers. Consider them for comparative context: